November 10th 2023
The US approval makes VLA1553 (Ixchiq; Valneva) the world’s first licensed chikungunya vaccine.
2023 IASLC North America Conference on Lung Cancer Satellite Symposia
Register Now!
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
Expert Illustrations & Commentaries™: Emerging Strategies for the Treatment of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Virtual Tumor Board®: Optimizing HER2 Testing Strategies for Clinical Decision Making in GI Malignancies
View More
(COPE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
(CME/CNE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
Sickle Cell Disease: Improving the Quality and Continuum of Acute and Ambulatory Patient Care
View More
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
PER Postgame™: The Latest from Louisville 2022 – Utilizing Recent Data to Improve Care for Patients with Peanut Allergy
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Advances In™ Desmoid Tumors: Recognizing Disease Burden, Pathophysiology, and Targeted Treatments in Development
View More
Gene Therapy for Hemophilia: What Does the Future Hold?
View More
Advances In™: Meeting Unmet Clinical Needs in TNBC and HR+ Breast Cancer with TROP2-Targeted Regimens
View More
Oncology Consultations®: Clinical Impact of HER2-Low Expressing Breast Cancer and Novel Targeted Therapies to Address Unmet Needs in Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?
View More
2nd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™
Register Now!
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
Community Practice Connections™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease
View More
FDA accepts NDA for roflumilast foam 0.3% for seborrheic dermatitis in 9 years and up
April 18th 2023Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
March 22nd 2023Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
FDA warns against pediatric use of Hospira’s potassium phosphates drug product
February 13th 2023In a recent statement, the US Food and Drug Administration warned pharmacies and health care providers about unsafe aluminum levels for pediatric patients in Hospira’s unapproved potassium phosphates drug product.
FDA approves Odactra for treating pediatric house dust mite-induced allergic rhinitis
January 26th 2023Odactra (House Dust Mite Allergen Extract; ALK) has received approval from the US Food and Drug Administration for use in patients aged 12 to 17 years with house dust mite-induced allergic rhinitis.